These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37650687)

  • 41. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
    Xu J; Ma H; Shan B
    PLoS One; 2022; 17(10):e0273163. PubMed ID: 36194583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer.
    Song L; Dai Z; Zhang S; Zhang H; Liu C; Ma X; Liu D; Zan Y; Yin X
    Biochem Biophys Res Commun; 2018 Sep; 504(1):164-170. PubMed ID: 30180955
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High expression of SPAG5 sustains the malignant growth and invasion of breast cancer cells through the activation of Wnt/β-catenin signalling.
    Jiang J; Wang J; He X; Ma W; Sun L; Zhou Q; Li M; Yu S
    Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):597-606. PubMed ID: 30854682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy.
    Zhu C; Menyhart O; Győrffy B; He X
    BMC Cancer; 2019 Nov; 19(1):1046. PubMed ID: 31690268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker.
    Qiu Y; Wang H; Liao P; Xu B; Hu R; Yang Y; Li Y
    BMC Genom Data; 2022 Jan; 23(1):7. PubMed ID: 35033016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.
    Canu V; Donzelli S; Sacconi A; Lo Sardo F; Pulito C; Bossel N; Di Benedetto A; Muti P; Botti C; Domany E; Bicciato S; Strano S; Yarden Y; Blandino G
    Cell Death Differ; 2021 May; 28(5):1493-1511. PubMed ID: 33230261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-367-3p overexpression represses the proliferation and invasion of cervical cancer cells through downregulation of SPAG5-mediated Wnt/β-catenin signalling.
    Yang T; Tian S; Wang L; Wang Y; Zhao J
    Clin Exp Pharmacol Physiol; 2020 Apr; 47(4):687-695. PubMed ID: 31792998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer.
    Xu Y; Shen M; Peng Y; Liu L; Tang L; Yang T; Pu D; Tan W; Zhang W; Liu S
    Biomed Res Int; 2022; 2022():4632453. PubMed ID: 36082153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets.
    Jiang F; Shi Y; Wang Y; Ge C; Zhu J; Fang H; Zhang Y; Zhang Y; Jian H; Lei T; Lan S; Cao L; Yu H; Fang D
    Aging (Albany NY); 2023 Mar; 15(6):2066-2081. PubMed ID: 36920183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SPAG5: An Emerging Oncogene.
    He J; Green AR; Li Y; Chan SYT; Liu DX
    Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.
    Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q
    Front Immunol; 2022; 13():907182. PubMed ID: 36389798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive pan-cancer analysis unveils the significant prognostic value and potential role in immune microenvironment modulation of TRIB3.
    Hu C; Li Q; Xiang L; Luo Y; Li S; An J; Yu X; Zhang G; Chen Y; Wang Y; Wang D
    Comput Struct Biotechnol J; 2024 Dec; 23():234-250. PubMed ID: 38161736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N6AMT1 is a novel potential diagnostic, prognostic and immunotherapy response biomarker in pan-cancer.
    Wang M; Zhu J; Ye Y; Li P; Sun W; Zhang M
    Aging (Albany NY); 2023 Jul; 15(13):6526-6544. PubMed ID: 37437243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
    Zhao Q; Zhang Z; Wu Y
    Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [STIP1 correlates with tumor immune infiltration and prognosis as a potential immunotherapy target: a pan-cancer bioinformatics analysis].
    Guan S; Shen Z; Lin M; Deng H; Fang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jul; 43(7):1179-1193. PubMed ID: 37488801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive bioinformatics analysis of NOX4 as a biomarker for pan-cancer prognosis and immune infiltration.
    Liu Y; Huang H; Yang X; Huang D; Wang X; Yuan M; Hong L
    Aging (Albany NY); 2024 Apr; 16(8):7437-7447. PubMed ID: 38663913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
    Hu X; Zhu H; Zhang X; He X; Xu X
    Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OSBP-related protein 8 (ORP8) interacts with Homo sapiens sperm associated antigen 5 (SPAG5) and mediates oxysterol interference of HepG2 cell cycle.
    Zhong W; Zhou Y; Li J; Mysore R; Luo W; Li S; Chang MS; Olkkonen VM; Yan D
    Exp Cell Res; 2014 Apr; 322(2):227-35. PubMed ID: 24424245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.